Journal: PLoS ONE

Article Title: Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action

doi: 10.1371/journal.pone.0020729

Figure Lengend Snippet: A&B, FBA-TPQ induces dose-dependent ROS stress in OVCAR-3 cells (A, the dose-dependent increase in the ROS as indicated by CM-H 2 DCFDA; B, Data summarized as the percentage compared with the control). C, Western blot analysis of cellular protein expression levels of the related pathway, indicating FBA-TPQ may take effects through the ROS-accompanied, and PI3K-Akt-mediated/p53-MDM2-related cell proliferation, apoptosis and cell cycle progression associated pathway on OVCAR-3 ovarian cancer cell lines after 24 h exposure (at 250,750 and 1000 nM concentrations).

Article Snippet: The Anti-human MDM2 antibody was obtained from Calbiochem® of EMD Chemicals Inc. (Darmstadt, Germany), the Caspase-3 (8G10) antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), and the anti-human β-actin (AC-74) antibody was obtained from Sigma-Aldrich, Inc. (St. Louis, MO).

Techniques: Control, Western Blot, Expressing

Journal: PLoS ONE

Article Title: Experimental Therapy of Ovarian Cancer with Synthetic Makaluvamine Analog: In Vitro and In Vivo Anticancer Activity and Molecular Mechanisms of Action

doi: 10.1371/journal.pone.0020729

Figure Lengend Snippet: A and B, Fluorescence intensity (JC-1 produces red fluorescence within the mitochondria as JC-1-aggregates while emits green fluorescence when leaks into the cytoplasm as JC-1-monomers; Fluorescence intensity shift between green and red is proportional to the ΔΨm change) values of JC-1 dye at specific excitation wavelengths and the corresponding ratio of Red/Green change (% of the control) after exposure to FBA-TPQ for 24 h (*, p <0.05 versus the control). C&D, Inhibition of tumor growth in mice bearing OVCAR-3 xenograft tumors (*, p <0.05 versus the control; **, p <0.01 versus the control), and the corresponding body weight changes during the treatments ( p >0.05); E, Western-blot analysis of proteins (of the mice xenograft tumors after FBA-TPQ treatment of 0, 1 or 10 mg/kg dosage) involved in the FBA-TPQ-triggered, and PI3K-Akt mediated/p53-MDM2-related pathway.

Article Snippet: The Anti-human MDM2 antibody was obtained from Calbiochem® of EMD Chemicals Inc. (Darmstadt, Germany), the Caspase-3 (8G10) antibody was purchased from Cell Signaling Technology, Inc. (Danvers, MA, USA), and the anti-human β-actin (AC-74) antibody was obtained from Sigma-Aldrich, Inc. (St. Louis, MO).

Techniques: Fluorescence, Control, Inhibition, Western Blot